drugset / Trial / NCT00798707

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

NCT00798707

Phase 3 Completed 709 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.

Timeline

Start
2008-12
Primary completion
2010-04
Completion
2010-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Desvenlafaxine Other / unclassified 25 mg
Subject Desvenlafaxine Other / unclassified 50 mg